13143-03-8

Basic information

• Product Name: N-(4-acetylphenyl)-N'-phenylurea
• Synonyms: N-(4-acetylphenyl)-N'-phenylurea
• CAS NO: 13143-03-8
• Molecular Formula: C₁₅H₁₄N₂O₂
• Molecular Weight: 254.28
• Mol File: 13143-03-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 339.3°C at 760 mmHg
• Flash Point: 118.9°C
• Appearance: /
• Density: 1.262g/cm³
• Vapor Pressure: 9.25E-05mmHg at 25°C
• Refractive Index: 1.668
• CAS DataBase Reference: N-(4-acetylphenyl)-N'-phenylurea(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-acetylphenyl)-N'-phenylurea(13143-03-8)
• EPA Substance Registry System: N-(4-acetylphenyl)-N'-phenylurea(13143-03-8)

Safety Data

• Hazardous Substances Data: 13143-03-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C15H14N2O2/c1-11(18)12-7-9-14(10-8-12)17-15(19)16-13-5-3-2-4-6-13/h2-10H,1H3,(H2,16,17,19)

Upstream product

• 495-18-1 Benzohydroxamic acid 
• 99-92-3 p-aminobenzophenone 
• 62-53-3 aniline 
• 103-71-9 phenyl isocyanate 

Downstream Products

• 1039454-24-4 ethyl 2-oxo-2-[4-(3-phenylureido)phenyl]ethyl trithiocarbonate 
• 915185-18-1 N-{4-[3-(dimethylamino)propanoyl]phenyl}-N'-phenylurea 
• 1350728-34-5 4-bromo-4'-(phenylurenyl)chalcone 
• 1350728-40-3 4-methoxy-4'-(phenylurenyl)chalcone 
• 1350728-36-7 4-chloro-4'-(phenylurenyl)chalcone 
• 1350728-38-9 4-methyl-4'-(phenylurenyl)chalcone 

Relevant articles and documents

Synthesis, molecular docking, and biological activities of new cyanopyridine derivatives containing phenylurea

A new class of cyanopyridine derivatives (10a–e and 11a–e) containing the phenylurea unit was synthesized and tested against some metabolic enzymes including acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α-glycosidase (α-Gly). The new cya

Synthesis and biological evaluation of some novel thiobenzimidazole derivatives as anti-renal cancer agents through inhibition of c-MET kinase

Benzimidazole is an interesting scaffold constituting a main core in many anticancer agents against variable cell lines as Carbendazim (I) and Nocodazole (II). Accordingly, eighteen compounds of 2-((1H-benzoimidazol-2-yl)thio)-1-(aryl/heteroaryl)ethan-1-ones, in their sulfate salt and free forms, were designed and investigated as anticancer agents. In vitro preliminary screening of selected compounds by the National Cancer Institute (NCI) on a panel of 60 cell lines revealed renal cancer cell line (A498) as the most vulnerable cell line; accordingly, IC50 values against A498 cell line were determined for compounds with the best results. The best inhibitory activity was for compound 4a with (IC50 = 6.97 μM) compared to sunitinib as a reference drug (IC50 = 6.99 μM). Compound 4a was further subjected to cell cycle analysis that indicated the decrease in cell population in the G2/M phase when compared to the untreated control cells. In addition, it showed significant increase in the late apoptosis in Annexin-V FTIC study compared to the control cells. An enzymatic inhibitory study on compound 4a against c-Met and MAP kinases revealed its better activity against c-Met kinase with (IC50 = 0.27 μM) compared to sunitinib (IC50 = 0.18 μM). Molecular docking study was conducted to reveal the interactions of compound 4a in the active site of c-Met kinase. Computational ADME study was performed to insure that compound 4a has proper pharmacokinetic and drug-likeness properties.

Synthesis and Biological Evaluation of Novel 1-(4-(Hydroxy(1-oxo-1,3-dihydro-2H-inden-2-ylidene)methyl)phenyl)-3-phenylurea Derivatives

A series of novel phenylurea containing 2-benzoylindan-1-one derivatives 3a?–?3j were synthesized from the reaction of phenylurea-substituted acetophenones 1a?–?1j with phthalaldehyde 2 under mild reaction conditions in good yields. All synthesized compou